Biomerica, Inc. · NASDAQ:BMRA
Biomerica — Investor Presentation (March 2016)
18 slides from Biomerica's investor presentation, Mar 16, 2016
Slide 1: Investor Presentation March 2016
Investor Presentation March 2016
Slide 2: Forward looking Statements
BIOMERICA-> Forward looking Statements The Private Securities Litigation Reform Act of 1995 provides a “safe harbor" for forward- looking statements. Certain information included in this presentation (as well as information included in oral statements or other written statements made or to be made b
Slide 3: Thank you. First presentation to an investor group
Thank you. First presentation to an investor group *
Slide 4: Scientific Advisory Board & ROME foundation
Scientific Advisory Board & ROME foundation Dr. Doug Drossman Dr. Chuck Carter (Former Executive Director of Rome foundation (Leading IBS not for profit (SAB Chair) Medical Affairs for Salix group) Pharmaceuticals) a — ——— Dr. Doug Drossman (President of the ROME foundation) leading opinion leader i
Slide 5: Companies in the IBS market
Companies in the IBS market Acq, for $15.6B Market Cap*: $1.4B by Valeant Market Cap*: $330MM Market Cap*: $8MM Product: Linaclotide Product: Rifaximin Product: Product: IBS (Linzess) (Xifaxan) Plecanatide blood test * IBS-C only * IBS-D only * IBS-C only * Access to entire IBS * PI's: Two of the US
Slide 6: Irritable Bowel Syndrome (IBS) Market
Irritable Bowel Syndrome (IBS) Market US PREVALENCE WORLDWIDE OF IBSt DISEASE OVER 45 OVER 14% — 1. Aliment Pharmacol Ther. 2005:21(11):1365-1375. BIOMERICA-> — O°.o0
Slide 7: IBS Market
IBS Market Pharmaceuticals can only focus on 1/3 of the IBS market 3 types of IBS Market APPROXIMATELY % 33% c,D,M D + Drugs can only IBS -C work on IBS-C or (Constipation) IBS-D - + They can’t do both (IBS-M) IBS -D (Diarrhea) IBS -M (Mixed — alternates C & D)
Slide 8: IBS Patients
IBS Patients IBS patient visit doctors 3x more than normal patients + [BS estimated cost $30 billion in direct and indirect annually + IBS sufferers incur 74% more direct healthcare costs than non-IBS sufferers —_YQ— IBS patients report that foods trigger their symptoms @Q- Affects predominantly fem
Slide 9: Models for Treatment - Key Differences
Models for Treatment - Key Differences eg Rx Drugs only treat symptoms not the underling cause Patients often cycle from one drug to another without long-term relief Side-effects are significant (e.g. Linzess) Severe or ongoing diarrhea Severe stomach pain Black, bloody, or tarry stool gas Bloating
Slide 10: Models for Treatment - Key Differences
Models for Treatment - Key Differences Our Product: 3 key differences Retest Determine the foods that can exacerbate IBS * Focuses on underlying cause Reimbursement + Drugs = $0 + Diagnostic = Significant revenue stream to physician * CPT code already exists Ability to use on all 3 types of IBS * 10
Slide 11: InFoods Physician's Office Use
InFoods® Physician's Office Use imFoods” Simple Blood Test InFoods® Test Results Food Result + POSITIVE NEGATIVE NEGATIVE + POSITIVE NEGATIVE NEGATIVE NEGATIVE + POSITIVE NEGATIVE NEGATIVE + POSITIVE NEGATIVE + POSITIVE Ou 0
Slide 12: IP & Technology
IP & Technology Patents 8 patents pending - International Patent Application for IBS was reviewed by the ISA and all claims have been deemed novel and non-obvious. Technology + Lab product - First to be submitted * Quest, Lab Corp., Mayo Clinic * Doctor office product - Post FDA approval of lab prod
Slide 13: Regulatory Pathway
Regulatory Pathway FDA is working with Biomerica on trial design FDA has indicated that the risk profile of the device is likely not a Class III + Avoids the much costlier and time-consuming PMA route....No Phase], II or III Our pathway would not be a PMA * De Novo pathway: novel lower-risk (for Cla
Slide 14: Team
Mr. Zackary Irani-Cohen CEO Mr. Francis Capitanio President Elisabeth Laderman, Ph.D, VP Technology Dr. Chuck Carter Executive Director of Medical Affairs Advisor Team + Sold Lancer Orthodontics netting a 4x return for investors + Biomerica : over 8 FDA approved diagnostics * Negotiated deals with B
Slide 15: Core Business
Core Business Latest Financials 6 months INCOME STATEMENT 6 months [pases 30 Nov15 Total Revenue 2,452 Cost of Revenue 1,619 Gross Profit 833 R&D 388 SG&A vEN Income from Operations -286 Other Income 18 Net Income before Tax benefit -268 Income Tax Benefit 129 Net Income -139 Ovo
Slide 16: Core Business
Core Business Balance Sheet Current Assets Cash And Cash Equiv. 643 Net Receivables 1173 Inventory 2237 Other Current Assets 105 Total Current Assets 4,158 Long Term Investments 165 Property Plant and Equipment 395 Goodwill E Intangible Assets 285 Other Assets 66 Deferred Long Term Tax Asset 873 Tot
Slide 17: Capital Table
Capital Table Shares Percentage Name of Beneficial Owner Beneficially Beneficially Owned Owned Janet Moore 780,277 10.2% Zackary Irani 812,776 10.6% Francis Capitanio 124,500 1.6% Allen Barbieri 147,889 1.9% Francis R Cano, Ph.D. 132,000 1.7% Jane Emerson, M.D., Ph.D. 70,000 <1.0% Joseph L. Rink 395
Slide 18: Summary
Summary oy Unique New Diagnostic Product- Simple blood test to indentify foods that can exacerbate IBS Key differentiation Focuses on underlying cause NOT a drug - no side effects Reimbursement Access to entire IBS market, not just a subset Leading Opinion Leaders in IBS on SAB Over 45 million in US